 Savara is a rare lung disease company whose lead asset, Molgradex, failed to meet its primary endpoint in the Phase 3 IMPALA trial. Since that time, Savara has met with the FDA and has designed a new Phase 3 trial, IMPALA 2, that capitalizes on the strong points of Molgradex in IMPALA. 